Protein Allostery in Rational Drug Design

被引:8
作者
Kinoshita, Takayoshi [1 ]
机构
[1] Osaka Prefecture Univ, Grad Sch Sci, Sakai, Osaka, Japan
来源
PROTEIN ALLOSTERY IN DRUG DISCOVERY | 2019年 / 1163卷
关键词
Protein kinase; Allosteric inhibitor; Structure-based drug discovery; High selectivity; CRYSTAL-STRUCTURES; KINASE INHIBITORS; BINDING; IDENTIFICATION; TARGET; POTENT; SITE; SELECTIVITY; MECHANISM; CK2-ALPHA;
D O I
10.1007/978-981-13-8719-7_3
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
This chapter focuses on protein kinases that transfer the phosphate group of ATP to the hydroxyl group of a substrate protein. Five hundred eighteen human protein kinases are classified into serine/threonine kinases and tyrosine kinases and individually or synergistically transduce physiologic stimuli into cell to promote cell proliferation or apoptosis, etc. Protein kinases are identified as drug targets because dysfunction of kinases leads to severe diseases such as cancers and autoimmune diseases. A large number of the crystal structures of the protein kinase inhibitor complex are available in Protein Data Bank and facilitated the drug discovery targeting protein kinases. The protein kinase inhibitors are classified into categories, Type-I, Type-II, Type-III, Type-IV, and Type-V, and as a separate class, covalent-type inhibitors. In any type, a protein kinase inhibitor bound to the allosteric region is advantageous in terms of selectivity compared to the traditional ATP-competitive one. In the following sections, the successful and promising examples of the partially or fully allosteric protein kinase inhibitors are illustrated in the following pages.
引用
收藏
页码:45 / 64
页数:20
相关论文
共 46 条
  • [1] Unique MAP kinase binding sites
    Akella, Radha
    Moon, Thomas M.
    Goldsmith, Elizabeth J.
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2008, 1784 (01): : 48 - 55
  • [2] Dimethyl fumarate is an allosteric covalent inhibitor of the p90 ribosomal S6 kinases
    Andersen, Jacob Lauwring
    Gesser, Borbala
    Funder, Erik Daa
    Nielsen, Christine Juul Faelled
    Gotfred-Rasmussen, Helle
    Rasmussen, Mads Kirchheiner
    Toth, Rachel
    Gothelf, Kurt Vesterager
    Arthur, J. Simon C.
    Iversen, Lars
    Nissen, Poul
    [J]. NATURE COMMUNICATIONS, 2018, 9
  • [3] A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase
    Atwell, S
    Adams, JM
    Badger, J
    Buchanan, MD
    Feil, IK
    Froning, KJ
    Gao, X
    Hendle, J
    Keegan, K
    Leon, BC
    Müller-Dieckmann, HJ
    Nienaber, VL
    Noland, BW
    Post, K
    Rajashankar, KR
    Ramos, A
    Russell, M
    Burley, SK
    Buchanan, SG
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (53) : 55827 - 55832
  • [4] Conformational Adaption May Explain the Slow Dissociation Kinetics of Roniciclib (BAY 1000394), a Type I CDK Inhibitor with Kinetic Selectivity for CDK2 and CDK9
    Ayaz, Pelin
    Andres, Dorothee
    Kwiatkowski, Dennis A.
    Kolbe, Carl-Christian
    Lienau, Philip
    Siemeister, Gerhard
    Luecking, Ulrich
    Stegmann, Christian M.
    [J]. ACS CHEMICAL BIOLOGY, 2016, 11 (06) : 1710 - 1719
  • [5] Discovery of a Potential Allosteric Ligand Binding Site in CDK2
    Betzi, Stephane
    Alam, Riazul
    Martin, Mathew
    Lubbers, Donna J.
    Han, Huijong
    Jakkaraj, Sudhakar R.
    Georg, Gunda I.
    Schoenbrunn, Ernst
    [J]. ACS CHEMICAL BIOLOGY, 2011, 6 (05) : 492 - 501
  • [6] Novel non-ATP competitive small molecules targeting the CK2 α/β interface
    Brear, Paul
    North, Andrew
    Iegre, Jessica
    Georgiou, Kathy Hadje
    Lubin, Alexandra
    Carro, Laura
    Green, William
    Sore, Hannah F.
    Hyvonen, Marko
    Spring, David R.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2018, 26 (11) : 3016 - 3020
  • [7] Role of Molecular Dynamics and Related Methods in Drug Discovery
    De Vivo, Marco
    Masetti, Matteo
    Bottegoni, Giovanni
    Cavalli, Andrea
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (09) : 4035 - 4061
  • [8] Crystal Structures of MEK1 Binary and Ternary Complexes with Nucleotides and Inhibitors
    Fischmann, Thierry O.
    Smith, Catherine K.
    Mayhood, Todd W.
    Myers, Joseph E., Jr.
    Reichert, Paul
    Mannarino, Anthony
    Carr, Donna
    Zhu, Hugh
    Wong, Jesse
    Yang, Rong-Sheng
    Le, Hung V.
    Madison, Vincent S.
    [J]. BIOCHEMISTRY, 2009, 48 (12) : 2661 - 2674
  • [9] The juxtamembrane region of TrkA kinase is critical for inhibitor selectivity
    Furuya, Noritaka
    Momose, Takaki
    Katsuno, Kenji
    Fushimi, Nobuhiko
    Muranaka, Hideyuki
    Handa, Chiaki
    Ozawa, Tomonaga
    Kinoshita, Takayoshi
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (05) : 1233 - 1236
  • [10] New approaches to the discovery of cdk5 inhibitors
    Glicksman, Marcie A.
    Cuny, Gregory D.
    Liu, Min
    Dobson, Brittany
    Auerbach, Kenneth
    Stein, Ross L.
    Kosik, Kenneth S.
    [J]. CURRENT ALZHEIMER RESEARCH, 2007, 4 (05) : 547 - 549